Prediction Model for Response to Biologics and Small Molecular Agent for UC

Sponsor
Asan Medical Center
Study ID
NCT05186623
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 79 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.

Key Dates

Start date
Feb 5, 2022
Status verified
Feb 2022
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Patients with confirmed ulcerative colitis
    Patients with confirmed ulcerative colitis, who are going to receive vedolizumab therapy (n=100: development cohort n=70 and validation cohort n=30), ustekinumab therapy (n=100: development cohort n=70 and validation cohort n=30), or tofacitinib therapy (n=100: development cohort n=70 and validation cohort n=30), will be enrolled.

Primary Outcome Measure

Response to induction therapy [ Time Frame: Week 14 to Week 16 ]

Central Contacts

Related Studies